Increased Cytoplasmic Localization of p27kip1 and Its Modulation of RhoA Activity during Progression of Chronic Myeloid Leukemia

MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27KIP1

(2012) M T Gómez-Casares et al.   ONCOGENE

p57 Kip2 is a downstream effector of BCR–ABL kinase inhibitors in chronic myelogenous leukemia cells

(2010) Adriana Borriello et al.   CARCINOGENESIS

p27: A Barometer of Signaling Deregulation and Potential Predictor of Response to Targeted Therapies

(2010) S. A. Wander et al.   CLINICAL CANCER RESEARCH

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors

(2010) S Chu et al.   LEUKEMIA

RhoA Regulates G1-S Progression of Gastric Cancer Cells by Modulation of Multiple INK4 Family Tumor Suppressors

(2009) S. Zhang et al.   MOLECULAR CANCER RESEARCH

RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility

(2009) M. D. Larrea et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease

(2008) A. Agarwal et al.   BLOOD

Blockade of the RhoA-JNK-c-Jun-MMP2 Cascade by Atorvastatin Reduces Osteosarcoma Cell Invasion

(2008) Olivia Fromigué et al.   JOURNAL OF BIOLOGICAL CHEMISTRY